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Summary 
The Southwest Oncology Group (SWOG) studied the response rate and toxicity of menogaril (200 mg/m 2 
i.v. q 28 days) in patients with advanced metastatic renal cell carcinoma. During the early stage of the trial 
two partial responses were seen in the first 20 treated patients, and an additional 36 evaluable patients were 
studied. Three of 56 (5%) evaluable patients achieved partial responses. Significant white cell toxicity was 
observed. Mild or moderate degrees of  thrombocytopenia, gastrointestinal side effects, alopecia and phlebitis 
occurred. No cardiac toxicity was noted. The low response rate suggests that menogaril in this dose schedule 
has no role in the treatment of patients with advanced metastatic renal cancer. 
Introduction 
Menogaril is an anthracycline antibiotic synthe- 
sized from nogalamycin, and is known by the fol- 
lowing synonyms; menogarol, 7-(12)-0-methyl- 
nogarol and 7-OMEN. Although an anthracycline 
its cytotoxicity may differ significantly from that of 
doxorubicin, as menogaril causes cell death with 
only minimal DNA binding [1,2]. Menogaril has 
demonstrated antineoplastic activity in several 
animal tumor systems; including P388 leukemia, 
L1210 leukemia, colon 26, colon 38, 1316 melano- 
ma, and CD8F 1 mammary tumor [3]. In a direct 
comparison of menogaril and doxorubicin the two 
agents were found to be equally effective against 
i.p. P388 leukemia, menogaril was more active 
against i.v. inoculated P388 and i.p. inoculated 
L1210, but less active than doxorubicin against i.p. 
inoculated B16 melanoma [4]. 
Two separate phase I trials have been published, 
and both studies recommended that the starting 
dose of menogaril in previously untreated patients 
be 200 mg/m 2 [5, 6]. Neither of these phase I trials 
noted responses in the patients studied. Dose limit- 
ing toxicity was primarily myelosuppression, al- 
though also reported were local phlebitis and/or  
erythema, infrequent alopecia, and minor arrhyth- 
mias. The Southwest Oncology Group (SWOG) 
studied menogaril in several different diseases, and 
this report details the phase II results seen in pa- 
tients with renal cancer. Study objectives were 
twofold, first to determine the response rate and se- 
cond to assess the toxicities of menogaril ad- 
ministered every 28 days. 
Materials and methods 
Eligibility included a histologic confirmation of 
renal cell carcinoma, no prior chemotherapy, bi- 
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dimensionally measurable disease, life expectancy 
of six weeks, performance status of  3 or better 
(SWOG criteria), and an absence of  a recent my- 
ocardial infarction (prior six months) or history of 
congestive heart failure or cardiac arrhythmia.  Pa- 
tients were to have recovered from prior surgery 
and radiation. Concomitant  radiation was allowed 
to lesions not being measured for purposes of  the 
study, and could not exceed a bone marrow volume 
of  10%. Concomitant  hormonal  therapy or chemo- 
therapy were not allowed. Labora tory  criteria for 
eligibility included a granulocyte count greater than 
or equal to 2000/ul, platelet count greater than or 
equal to 100,000/ul, bilirubin less than 2.0 mg%,  
SGOT less than 1.5 • normal,  and a creatinine of 
less than 2.0 rag%. All patients were provided in- 
formation as to the investigational nature of  the 
study and were required to sign a written document 
of  informed consent in keeping with institutional 
and FDA guidelines. 
All patients received an initial dose of  menogaril 
at 200 m g / m  2 i.v. over one hour in 500 cc of  5% 
dextrose in water. Subsequent doses were ad- 
ministered at 28 day intervals and increased by 20% 
if the nadir granulocyte count was greater than 
1500/ul and platelet nadir exceeded 100,000/ul. For 
nadir granulocyte counts between 1000-1499/ul  or 
platelet counts between 50,000-99,999/ul ,  the dose 
remained the same. For nadir granulocyte counts 
lower than 1000/ul or platelet counts less than 
50,000/ul, the subsequent dose of  menogaril was 
decreased by 20%. 
Study patients underwent history and physical 
examination every 28 days, tumor measurements at 
this same interval, weekly blood counts, and 
chemistries every 28 days. Response criteria were 
standard for a phase II trial: including a complete 
remission (CR) which required disappearance of all 
clinically detectable disease for at least four weeks, 
a partial remission (PR) which required a 50% 
shrinkage in the sum of  the products of  all di- 
ameters of  measured lesions for a minimum of four 
weeks, 30% reduction in the sums of  liver measure- 
ments below the costal margins, partial calcifica- 
tion of lytic bone lesions or 50% reduction in blastic 
lesions, and no simultaneous increase in the size of  
any lesion or the appearance of new lesions. Pro- 
gression was defined as at least a 25% increase in 
the size of  any measurable lesion, appearance of a 
new lesion, uncontrolled hypercalcemia, or clear 
progression of  lytic bone lesions. Relapse was de- 
fined as the appearance of new lesions, reappear- 
ance of  old lesions in patients with a previous CR, 
or 50% increase over the sum of the products of  di- 
ameters noted at maximal PR. 
For statistical purposes this study was designed 
for two stages. The first stage was to enroll 20 eligi- 
ble patients and temporari ly close the trial for 
response determination. I f  no responses or remis- 
sions were seen the trial would be closed as nega- 
tive. I f  any remissions were seen the second stage 
was designed to enter an additional 20 eligible pa- 
tients and remission rate reevaluated. I f  four or 
fewer remissions (CR and PR) were seen the drug 
would be rejected as inactive for further study at 
this schedule in patients with renal cancer. 
Results 
Thirty-one of  56 patients (55%) had undergone ne- 
phrectomy, 9/56 (16~ had received some form of 
prior immunotherapy,  and 11/56 (20%) had ex- 
perienced prior hormone treatment.  Except for 11 
patients all of  those entered on the trial received two 
or more cycles of  chemotherapy. Of  the 11 patients 
receiving less than two cycles of  therapy, seven were 
clearly progressing before the 28 day cycle could be 
repeated, two experienced early death, and two pa- 
tients left the care of  the participating investigator 
before receiving a second dose. 
After the first 20 patients were registered two 
PR ' s  were seen, and the trial was reopened to assure 
a more adequate determination of response. Ulti- 
mately a total of  57 patients were studied, 56 of 
whom were evaluable for response and toxicity. 
One patient was ineligible due to a diagnosis of  
prostate cancer, and was inadvertently registered 
on this study instead of the simultaneously ongoing 
SWOG menogaril  trial in this disease. Three PR ' s  
were seen. One patient had a primary renal lesion 
which responded for seven months, one patient had 
a PR in a subcutaneous nodule which lasted for two 
months, and the 3rd patient with a PR had a re- 















None Mild Mod Severe LT 
9 11 19 14 3 
52 0 4 0 0 
33 10 7 1 0 
15 3 11 18 9 
None Mild Mod Severe LT 
30 10 10 6 0 
41 7 5 3 0 
51 1 3 1 0 
52 2 1 0 1 
53 2 1 0 0 
55 0 1 0 0 
sponding lung lesion of five and one-half months. 
No CR's were seen, and the overall response rate 
was five percent, with an exact 95% confidence in- 
terval of 1% to 15%. 
A median of two courses of menogaril (range 
1-11 courses) was given for the 56 evaluable pa- 
tients. The amount of menogaril administered per 
patient ranged from 190.5 mg/m 2 to 1600 mg/m 2 
with a median dose of 630 mg/m 2. There were 17 
dose escalations and 36 dose reductions given per 
protocol criteria. 
Toxicity is summarized in Table 1. Toxicity grad- 
ing is by standard SWOG criteria. The major side 
effect in this patient population was in the white 
cells, where 17/56 (30%) patients sustained severe 
or life-threatening toxicity. Significant thrombocy- 
topenia was rarely seen, and gastrointestinal toxici- 
ty was generally mild or absent. Other toxicities in- 
cluded anemia (46%), alopecia (27%) and 
infrequent phlebitis (9%). No instances of acute or 
chronic cardiac toxicity were observed. 
Discussion 
Patients with advanced metastatic renal cell carci- 
noma remain relatively resistant to any form of sys- 
temic therapy. This dose schedule of menogaril was 
relatively well tolerated, although significant white 
cell depression did occur. This compound appears 
to have less gastrointestinal toxicity than doxorubi- 
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cin. That menogaril demonstrated no long term 
cardiac toxicity may be related to the lower dose 
and shorter exposure in patients with resistant renal 
cell carcinoma. There are no known anthracycline 
chemotherapeutic agents that have any efficacy in 
renal carcinoma. The finding of only three 
responders out of 56 (5%) strongly suggests that 
menogaril in this dose schedule also has no role in 
the treatment of patients with advanced renal cell 
carcinoma. 
Acknowledgements 
This investigation was supported in part by the fol- 
lowing PHS Cooperative Agreement grant num- 
bers awarded by the National Cancer Institute, 
DHHS: CA-12644, CA-37429, CA-12213, CA- 
13612, CA-04915, CA-27057, CA-32734, CA- 
04919, CA-16385, CA-03096, CA-04920, CA- 
35995, CA-21116, CA-37981, CA-22411, CA- 
20319, CA-28862, CA-14028, CA-32102. 
References 
1. Kruger WC, Pschigoda LM, Schpok SLF, Moscowitz A, 
McGovren JI, Neta P, Merritt MV, Li LH: The interaction 
of nogatamycin and analogs with DNA and other bio- 
polymers. Chem-Biol. Interaction 36: 1-18, 1981 
2. Li LH, Murch LL, Wooden JM, Krueger WC, Pschigoda LM: 
Inhibition of DNA and RNA polymerases by nogalamycin and 
its analogs. (Abstr) Proc Am Assoc Cancer Res 19: 30, 1978 
3. Neil GL, Kuentzel SL, McGovren JP: Treatment of mouse 
tumors with 7-con-0-Methylnogarol and other analogs of the 
anthracycline antibiotics, nogalamycin. Cancer Treat Rep 63: 
1971-1978, 1979 
4. Bhuryan BK, McGovren JP, Crampton SL: Intracellular up- 
take of 7-con-0-Methylnogarol and Adriamycin by cells in 
culture and its relationship to cell survival. Cancer Res 41: 
882-887, 1981 
5. Dorr FA, VonHoff DD, Kuhn JG, Schwartz R, Krisner DL: 
Phase I clinical investigation of 7-con-0-Methylnogaril, a new 
anthracycline antibiotic. Cancer Res 46: 2562-2565, 1986 
6. Dodion P, Sessa C, Joss R, Crespeigne N, Willems Y, Kitt M, 
Abrams J, Finet C, Brewer JE, Adams WJ, Earhart RH, 
Rozencweig M, Kenis Y, Cavalli F: Phase I study of in- 
travenous menogaril administered intermittently. J Clin On- 
col 4: 767-774, 1986 
Address for  offprints: Southwest Oncology Group (SWOG- 
8504), Operations Office, 5430 Fredericksburg Road, Suite 
#618, San Antonio, TX 78229, USA 
